Now showing items 1-10 of 18
An audit of the effectiveness of PCSK9 inhibition in reducing cholesterol in patients attending lipid clinics
Introduction: Evolocumab and alirocumab are monoclonal antibodies that inhibit PCSK-9 and reduce LDl-C. This audit assessed the effectiveness of PCSK9 inhibitor administration in patients attending lipid clinics at regional ...
Pain evaluation in preterm infants using skin conductance algesimeter
Pain asessment is a challenge in patients who are unable to communicate verbally, e.g. neonates. Consequently, they may receive less effective analgesic treatment. Visual, behavioural and physiological pain scales are used ...
Identification of rare diseases by screening a population selected on the basis of routine pathology results-the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy.
AIMS: Lysosomal acid lipase deficiency (LALD) is an autosomal recessive disorder of cholesterol ester storage associated with hepatic disease, cirrhosis and accelerated atherosclerosis. Its prevalence in the general ...
An update on trials of novel lipid-lowering drugs
PURPOSE OF REVIEW: A number of novel trials have assessed the efficacy of new lipid-lowering therapies in cardiovascular disease (CVD). RECENT FINDINGS: Proprotein convertase subtilisin kexin-9 inhibitors reduce low-density ...
Sweat Testing Since The Introduction Of Newborn Screening In West Midlands, UK
Background Cystic Fibrosis (CF) is an autosomal recessive condition caused by gene mutation which affects sodium and chloride transport across the membrane of secretory epithelial cells. New born screening for CF was ...
Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis
Cholesteryl ester storage disease (CESD) is an autosomal recessive lysosomal storage disorder caused by a variety of mutations of the LIPA gene. These cause reduced activity of lysosomal acid lipase, which results in ...